The Clinical Manifestations and Efficacy of Different Treatments Used for Nephrogenic Systemic Fibrosis: A Systematic Review

References

• Taraphder A, Waikhom R. Nephrogenic systemic fibrosis: a brief review. Indian J Dermatol. 2011;56(1):54. doi:10.4103/0019-5154.77554
   PubMedGoogle Scholar
• Rota E, Nallino MG, Bainotti S, Formica M. Nephrogenic systemic fibrosis: an unusual scleroderma-like fibrosing disorder. Rheumatol Int. 2010;30(10):1389–1391. doi:10.1007/s00296-009-1083-4
   PubMed Web of Science ®Google Scholar
• Shah AH, Olivero JJ. Gadolinium-induced nephrogenic systemic fibrosis. Methodist Debakey Cardiovasc J. 2017;13(3):172–173. doi:10.14797/mdcvj.751
   PubMedGoogle Scholar
• Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356(9234):1000–1001. doi:10.1016/S0140-6736(00)02694-5
   PubMed Web of Science ®Google Scholar
• Deng A, Martin DB, Spillane A, et al. Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: a disorder of aberrant dermal remodeling. J Cutan Pathol. 2010;37(2):204–210. doi:10.1111/j.1600-0560.2009.01301.x
   PubMed Web of Science ®Google Scholar
• Bhawan J, Swick BL, Koff AB, Stone MS. Sclerotic bodies in nephrogenic systemic fibrosis: a new histopathologic finding. J Cutan Pathol. 2009;36(5):548–552. doi:10.1111/j.1600-0560.2008.01111.x
   PubMed Web of Science ®Google Scholar
• Jiménez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum. 2004;50(8):220–222. doi:10.1002/art.20362
   Google Scholar
• Todd DJ, Kay J. Gadolinium-induced fibrosis. Annu Rev Med. 2016;67:273–291. doi:10.1146/annurev-med-063014-124936
   PubMed Web of Science ®Google Scholar
• Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial. 2008;21(2):123–128.
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Motegi S, Toki S, Endo Y, Yasuda M, Ishikawa O. Calciphylaxis and nephrogenic fibrosing dermopathy with pseudoxanthoma elasticum-like changes: successful treatment with sodium thiosulfate. J Dermatol. 2019;46(7):e240–e242. doi:10.1111/1346-8138.14780
   PubMed Web of Science ®Google Scholar
• Panesar M, Banerjee S, Barone GW. Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation. Clin Transplant. 2008;22(6):803–808. doi:10.1111/j.1399-0012.2008.00886.x
   PubMed Web of Science ®Google Scholar
• Woolen SA, Shankar PR, Gagnier JJ, MacEachern MP, Singer L, Davenport MS. Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis. JAMA Intern Med. 2020;180(2):223–230. doi:10.1001/jamainternmed.2019.5284
   PubMed Web of Science ®Google Scholar
• Mazhar SM, Shiehmorteza M, Kohl CA, Middleton MS, Sirlin CB. Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging. 2009;30(6):1313–1322. doi:10.1002/jmri.21983
   PubMed Web of Science ®Google Scholar
• Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: a frivolous entity. World J Nephrol. 2021;10(3):29–36. doi:10.5527/wjn.v10.i3.29
   PubMedGoogle Scholar
• Nephrogenic systemic fibrosis: a case report and review of the literature; 2022. Available from: https://pubmed.ncbi.nlm.nih.gov/21637902/. Accessed January 10, 2023.
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n160. doi:10.1136/bmj.n160
   PubMed Web of Science ®Google Scholar
• Study quality assessment tools. NHLBI, NIH; 2022. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed January 10, 2023.
   Google Scholar
• Swaminathan S, Arbiser JL, Hiatt KM, et al. Rapid improvement of nephrogenic systemic fibrosis with rapamycin therapy: possible role of phospho-70-ribosomal-S6 kinase. J Am Acad Dermatol. 2010;62(2):343–345. doi:10.1016/j.jaad.2009.04.022
   PubMed Web of Science ®Google Scholar
• Wilson J, Gleghorn K, Seigel Q, Kelly B. Nephrogenic systemic fibrosis: a 15-year retrospective study at a single tertiary care center. J Am Acad Dermatol. 2017;77(2):235–240. doi:10.1016/j.jaad.2017.02.003
   PubMed Web of Science ®Google Scholar
• Gilliet M, Cozzio A, Burg G, Nestle FO. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol. 2005;152(3):531–536. doi:10.1111/j.1365-2133.2005.06434.x
   PubMed Web of Science ®Google Scholar
• Kadiyala D, Roer DA, Perazella MA. Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate. Am J Kidney Dis. 2009;53(1):133–137. doi:10.1053/j.ajkd.2008.09.016
   PubMed Web of Science ®Google Scholar
• Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol. 2007;2(2):258–263. doi:10.2215/CJN.03250906
   PubMed Web of Science ®Google Scholar
• Schäd SG, Heitland P, Kühn-Velten WN, Gross GE, Jonas L. Time-dependent decrement of dermal gadolinium deposits and significant improvement of skin symptoms in a patient with nephrogenic systemic fibrosis after temporary renal failure. J Cutan Pathol. 2013;40(11):935–944. doi:10.1111/cup.12214
   PubMed Web of Science ®Google Scholar
• Tran KT, Prather HB, Cockerell CJ, Jacobe H. UV-A1 therapy for nephrogenic systemic fibrosis. Arch Dermatol. 2009;145(10):1170–1174. doi:10.1001/archdermatol.2009.245
   PubMedGoogle Scholar
• Mathur K, Morris S, Deighan C, Green R, Douglas KW. Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature. J Clin Apher. 2008;23(4):144–150. doi:10.1002/jca.20170
   PubMed Web of Science ®Google Scholar
• Ross C, de Rosa N, Marshman G, Astill D. Nephrogenic systemic fibrosis in a gadolinium-naïve patient: successful treatment with oral sirolimus. Australas J Dermatol. 2015;56(3):e59–e62. doi:10.1111/ajd.12176
   PubMed Web of Science ®Google Scholar
• Aires NB, Sotto MN, Nico MMS. Nephrogenic fibrosing dermopathy: report of two cases. Acta Derm Venereol. 2007;87(6):521–524. doi:10.2340/00015555-0296
   PubMed Web of Science ®Google Scholar
• Shin K, Granter SR, Coblyn JS, Gupta S. Progressive arm and leg stiffness in a patient with chronic renal impairment. Nat Clin Pract Rheumatol. 2008;4(10):557–562. doi:10.1038/ncprheum0883
   PubMedGoogle Scholar
• Nagai Y, Hasegawa M, Shinmi K, et al. Nephrogenic systemic fibrosis with multiple calcification and osseous metaplasia. Acta Derm Venereol. 2008;88(6):597–600. doi:10.2340/00015555-0518
   PubMed Web of Science ®Google Scholar
• Läuchli S, Zortea-Caflisch C, Nestle FO, Burg G, Kempf W. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology. 2004;208(3):278–280. doi:10.1159/000077321
   PubMed Web of Science ®Google Scholar
• Chandran S, Petersen J, Jacobs C, Fiorentino D, Doeden K, Lafayette RA. Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis. 2009;53(1):129–132. doi:10.1053/j.ajkd.2008.08.029
   PubMed Web of Science ®Google Scholar
• Duffy KL, Green L, Harris R, Powell D. Treatment of nephrogenic systemic fibrosis with Re-PUVA. J Am Acad Dermatol. 2008;59(2 Suppl 1):S39–S40. doi:10.1016/j.jaad.2007.08.035
   PubMed Web of Science ®Google Scholar
• Marckmann P, Nielsen AH, Sloth JJ. Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3–5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2008;23(10):3280–3282. doi:10.1093/ndt/gfn217
   PubMed Web of Science ®Google Scholar
• Chung HJ, Chung KY. Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br J Dermatol. 2004;150(3):596–597. doi:10.1111/j.1365-2133.2003.05795.x
   PubMed Web of Science ®Google Scholar
• DiCarlo JB, Gupta EA, Solomon AR. A pediatric case of nephrogenic fibrosing dermopathy: improvement after combination therapy. J Am Acad Dermatol. 2006;54(5):914–916. doi:10.1016/j.jaad.2006.01.023
   PubMed Web of Science ®Google Scholar
• Schmook T, Budde K, Ulrich C, Neumayer HH, Fritsche L, Stockfleth E. Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant. 2005;20(1):220–222. doi:10.1093/ndt/gfh473
   PubMed Web of Science ®Google Scholar
• Goddard DS, Magee CC, Lazar AJF, Miller DM. Nephrogenic fibrosing dermopathy with recurrence after allograft failure. J Am Acad Dermatol. 2007;56(5 Suppl):S109–S111. doi:10.1016/j.jaad.2006.04.061
   PubMed Web of Science ®Google Scholar
• Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008;58(8):2543–2548. doi:10.1002/art.23696
   PubMedGoogle Scholar
• Richmond H, Zwerner J, Kim Y, Fiorentino D. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol. 2007;143(8):1025–1030. doi:10.1001/archderm.143.8.1025
   PubMedGoogle Scholar
• Poisson JL, Low A, Park YA. The treatment of nephrogenic systemic fibrosis with therapeutic plasma exchange. J Clin Apher. 2013;28(4):317–320. doi:10.1002/jca.21253
   PubMed Web of Science ®Google Scholar
• Elmholdt TR, Pedersen M, Jørgensen B, Ramsing M, Olesen AB. Positive effect of low-dose imatinib mesylate in a patient with nephrogenic systemic fibrosis. Acta Derm Venereol. 2011;91(4):478–479. doi:10.2340/00015555-1085
   PubMed Web of Science ®Google Scholar
• Kreuter A, Gambichler T, Weiner SM, Schieren G. Limited effects of UV-A1 phototherapy in 3 patients with nephrogenic systemic fibrosis. Arch Dermatol. 2008;144(11):1527–1529. doi:10.1001/archderm.144.11.1527
   PubMedGoogle Scholar
• Zhang R, Rose WN. Photopheresis provides significant long-lasting benefit in nephrogenic systemic fibrosis. Case Rep Dermatol Med. 2017;2017:1–4. doi:10.1155/2017/6381479
   Google Scholar
• Koratala A, Bhatti V. Nephrogenic systemic fibrosis. Clin Case Rep. 2017;5(7):1184. doi:10.1002/ccr3.993
   PubMedGoogle Scholar
• Khurana A, Nickel AE, Greene JF, Narayanan M, High WA, Foulks CJ. Successful pregnancy in a hemodialysis patient and marked resolution of her nephrogenic systemic fibrosis. Am J Kidney Dis. 2008;51(6):e29–e32. doi:10.1053/j.ajkd.2007.12.037
   PubMed Web of Science ®Google Scholar
• Bangsgaard N, Hansen JM, Marckmann P, Skov L. Nephrogenic systemic fibrosis symptoms alleviated by renal transplantation. Dial Transplant. 2011;40(2):86–87. doi:10.1002/dat.20507
   Google Scholar
• Shah N, Ramkumar M, Wu C, et al. Is renal transplantation the cure to fatal nephrogenic systemic fibrosis: a case series of a rare disease. Transplantation. 2008;86(2S):696–697. doi:10.1097/01.tp.0000330832.09951.e0
   Google Scholar
• Mackay-Wiggan JM, Cohen DJ, Grossman ME, Knobler EH, Grossman ME. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol. 2003;48(1):55–60. doi:10.1067/mjd.2003.78
   PubMed Web of Science ®Google Scholar
• Ramaizel L, Sliwa JA. Rehabilitation in nephrogenic systemic fibrosis. PM&R. 2009;1(7):684–686. doi:10.1016/j.pmrj.2009.05.006
   Web of Science ®Google Scholar
• Schieren G, Wirtz N, Altmeyer P, Rump LC, Weiner SM, Kreuter A. Nephrogenic systemic fibrosis–a rapidly progressive disabling disease with limited therapeutic options. J Am Acad Dermatol. 2009;61(5):868–874. doi:10.1016/j.jaad.2009.03.040
   PubMed Web of Science ®Google Scholar
• Ragunatha S, Palit A, Inamadar A, Madraki R, Yelikar B. Nephrogenic fibrosing dermopathy. Indian J Dermatol Venereol Leprol. 2009;75(1):63–67. doi:10.4103/0378-6323.45224
   PubMed Web of Science ®Google Scholar
• Lim YJ, Bang J, Ko Y, et al. Late onset nephrogenic systemic fibrosis in a patient with stage 3 chronic kidney disease: a case report. J Korean Med Sci. 2020;35(35). doi:10.3346/jkms.2020.35.e293
   Web of Science ®Google Scholar
• Ustuner P, Kose OK, Gulec AT, Ozen O. A moderate response to plasmapheresis in nephrogenic systemic fibrosis. Clin Pract. 2011;1(4):e124. doi:10.4081/cp.2011.e124
   PubMedGoogle Scholar
• Foshee JP, Griffin TD Jr, Cam K, Rivlin M, Keller M. Adjunct treatment of recalcitrant hand plaques in nephrogenic systemic fibrosis after imatinib therapy. SKIN J Cutan Med. 2019;3(6):438–442. doi:10.25251/skin.3.6.14
   Google Scholar
• Malikova H. Nephrogenic systemic fibrosis: the end of the story? Quant Imaging Med Surg. 2019;9(8):1470. doi:10.21037/qims.2019.07.11
   PubMed Web of Science ®Google Scholar
• Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001;23(5):383–393. doi:10.1097/00000372-200110000-00001
   PubMed Web of Science ®Google Scholar
• Kitajima K, Maeda T, Watanabe S, Ueno Y, Sugimura K. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents. Int J Urol. 2012;19(9):806–811. doi:10.1111/j.1442-2042.2012.03042.x
   PubMed Web of Science ®Google Scholar
• Saab G, Cheng S. Nephrogenic systemic fibrosis: a nephrologist’s perspective. Hemodial Int. 2007;11(Suppl 3):S2–S6. doi:10.1111/j.1542-4758.2007.00222.x
   PubMedGoogle Scholar
• Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H. Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014;69(7):661–668. doi:10.1016/j.crad.2014.01.003
   PubMed Web of Science ®Google Scholar
• Saab G, Abu-Alfa A. Nephrogenic systemic fibrosis--implications for nephrologists. Eur J Radiol. 2008;66(2):208–212. doi:10.1016/j.ejrad.2008.01.028
   PubMed Web of Science ®Google Scholar
• Nephrogenic Systemic Fibrosis – NORD. National organization for rare disorders; 2022. Available from: https://rarediseases.org/rare-diseases/nephrogenic-systemic-fibrosis/. Accessed January 10, 2023.
   Google Scholar
• Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003;15(6):785–790. doi:10.1097/00002281-200311000-00017
   PubMed Web of Science ®Google Scholar
• Panesar M, Yacoub R. What is the role of renal transplantation in a patient with nephrogenic systemic fibrosis? Semin Dial. 2011;24(4):373–374. doi:10.1111/j.1525-139X.2011.00913.x
   PubMed Web of Science ®Google Scholar
• Cuffy MC, Singh M, Formica R, et al. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrol Dial Transplant. 2011;26(3):1099–1101. doi:10.1093/ndt/gfq693
   PubMed Web of Science ®Google Scholar
• Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007;56(10):3433–3441. doi:10.1002/art.22925
   PubMedGoogle Scholar
• He A, Kwatra SG, Zampella JG, Loss MJ. Nephrogenic systemic fibrosis: fibrotic plaques and contracture following exposure to gadolinium-based contrast media. BMJ Case Rep. 2016;2016:bcr2016214927.
   PubMedGoogle Scholar
• Alfano G, Fontana F, Ferrari A, et al. Incidence of nephrogenic systemic fibrosis after administration of gadoteric acid in patients on renal replacement treatment. Magn Reson Imaging. 2020;70:1–4. doi:10.1016/j.mri.2020.02.012
   PubMed Web of Science ®Google Scholar